Supernus Pharmaceuticals Inc (NASDAQ:SUPN) saw some unusual options trading activity on Tuesday. Investors bought 2,740 put options on the company. This is an increase of approximately 3,413% compared to the average daily volume of 78 put options.
A number of research analysts have recently commented on SUPN shares. BidaskClub downgraded shares of Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Friday, July 6th. Jefferies Financial Group lifted their price objective on shares of Supernus Pharmaceuticals from $55.00 to $58.00 and gave the company a “buy” rating in a research report on Thursday, August 9th. Cantor Fitzgerald set a $56.00 price objective on shares of Supernus Pharmaceuticals and gave the company a “buy” rating in a research report on Wednesday, August 8th. Mizuho initiated coverage on shares of Supernus Pharmaceuticals in a research note on Monday, September 17th. They set a “buy” rating and a $61.00 target price for the company. Finally, ValuEngine upgraded shares of Supernus Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Wednesday, September 19th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and ten have assigned a buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $55.30.
NASDAQ SUPN opened at $47.41 on Wednesday. The company has a quick ratio of 2.54, a current ratio of 2.74 and a debt-to-equity ratio of 0.82. The stock has a market cap of $2.47 billion, a PE ratio of 37.63 and a beta of 0.79. Supernus Pharmaceuticals has a 52-week low of $33.30 and a 52-week high of $61.25.
Several hedge funds and other institutional investors have recently bought and sold shares of SUPN. SevenBridge Financial Group LLC acquired a new stake in shares of Supernus Pharmaceuticals during the 2nd quarter worth about $113,000. Cubist Systematic Strategies LLC acquired a new stake in shares of Supernus Pharmaceuticals during the 2nd quarter worth about $203,000. NumerixS Investment Technologies Inc acquired a new stake in Supernus Pharmaceuticals in the 2nd quarter worth about $204,000. Everence Capital Management Inc. acquired a new stake in Supernus Pharmaceuticals in the 2nd quarter worth about $205,000. Finally, Cim LLC acquired a new stake in Supernus Pharmaceuticals in the 2nd quarter worth about $207,000. Institutional investors own 99.90% of the company’s stock.
Supernus Pharmaceuticals Company Profile
Supernus Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy.
Recommended Story: How dollar cost averaging works
Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.